Walgreens Boots Alliance reported its financial performance for the quarter ending February 29, 2024, with notable figures in trade receivables and other accounts receivable. Trade receivables increased to $4.8 billion from $4.3 billion in the previous six months, while other receivables, including those from Cencora, rose from $1.1 billion to $1.4 billion. The company also recorded a rise in depreciation and amortization expenses, with depreciation expense at $374 million and intangible assets amortization at $239 million for the quarter. This resulted in a total depreciation and amortization expense of $613 million, up from $559 million in the same period the previous year. Accumulated depreciation and amortization on property, plant, and equipment reached $13.2 billion. Cash and cash equivalents decreased to $668 million from $739 million, with restricted cash also seeing a reduction to $47 million from $93 million. The redeemable non-controlling interest showed a slight increase to $172 million from the opening balance of $169 million, despite a net loss attributable to these interests. The company's business development and future plans were not detailed in the provided announcement.

Walgreens Boots Alliance reported its financial performance for the quarter ending February 29, 2024, with notable figures in trade receivables and other accounts receivable. Trade receivables increased to $4.8 billion from $4.3 billion in the previous six months, while other receivables, including those from Cencora, rose from $1.1 billion to $1.4 billion. The company also recorded a rise in depreciation and amortization expenses, with depreciation expense at $374 million and intangible assets amortization at $239 million for the quarter. This resulted in a total depreciation and amortization expense of $613 million, up from $559 million in the same period the previous year. Accumulated depreciation and amortization on property, plant, and equipment reached $13.2 billion. Cash and cash equivalents decreased to $668 million from $739 million, with restricted cash also seeing a reduction to $47 million from $93 million. The redeemable non-controlling interest showed a slight increase to $172 million from the opening balance of $169 million, despite a net loss attributable to these interests. The company's business development and future plans were not detailed in the provided announcement.